47.15
-0.21(-0.44%)
Currency In USD
| Previous Close | 47.36 |
| Open | 47 |
| Day High | 47.79 |
| Day Low | 46.54 |
| 52-Week High | 110.25 |
| 52-Week Low | 45.66 |
| Volume | 407,440 |
| Average Volume | 1.17M |
| Market Cap | 5.56B |
| PE | -8.76 |
| EPS | -5.38 |
| Moving Average 50 Days | 51.49 |
| Moving Average 200 Days | 56.71 |
| Change | -0.21 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $6,833.33 as of December 30, 2024 at a share price of $47.15. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $4,595.52 as of December 30, 2024 at a share price of $47.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Dec 23, 2024 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-c
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
GlobeNewswire Inc.
Dec 20, 2024 5:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the t
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
GlobeNewswire Inc.
Dec 03, 2024 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a confirmatory Phase 3 clinical trial of om